Ser2054

Site Information
VMsQANVsRAKAVRA SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 3195869

In vivo Characterization
Methods used to characterize site in vivo:	mass spectrometry ( 1 , 2 , 3 , 4 , 5 )
Disease tissue studied:	luminal A breast cancer ( 1 ) , luminal B breast cancer ( 1 ) , cervical cancer ( 4 ) , cervical adenocarcinoma ( 4 )
Relevant cell line - cell type - tissue:	breast ( 1 ) , HeLa (cervical) ( 2 , 3 , 5 ) , HeLa S3 (cervical) ( 4 )

Upstream Regulation
Treatments:	nocodazole ( 4 )

References
1	Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62 27251275 Curated Info
2	Sharma K, et al. (2014) Ultradeep human phosphoproteome reveals a distinct regulatory nature of Tyr and Ser/Thr-based signaling. Cell Rep 8, 1583-94 25159151 Curated Info
3	Kettenbach AN, et al. (2011) Quantitative phosphoproteomics identifies substrates and functional modules of aurora and polo-like kinase activities in mitotic cells. Sci Signal 4, rs5 21712546 Curated Info
4	Olsen JV, et al. (2010) Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis. Sci Signal 3, ra3 20068231 Curated Info
5	Dephoure N, et al. (2008) A quantitative atlas of mitotic phosphorylation. Proc Natl Acad Sci U S A 105, 10762-7 18669648 Curated Info